Beam Therapeutics (BEAM) Q3 2024 earnings summary

Executive summary

• Reported first clinical data from one-time gene editing treatments, focusing on hematology (sickle cell disease) and liver genetic diseases (AATD), with BEAM-101 and BEAM-302 advancing in clinical trials.

• Four abstracts, including initial BEAM-101 clinical data and BEAM-201 oncology data, accepted for ASH Annual Meeting.

• ESCAPE technology demonstrated robust preclinical proof of concept for non-genotoxic conditioning, with BEAM-103 and BEAM-104 nominated as candidates.

• BEAM-301 IND opened with FDA; patient dosing expected in early 2025.

• Strategic collaborations maintained with Pfizer, Apellis, Verve, Eli Lilly, Sana, and Orbital.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $925.8M as of September 30, 2024, down from $1.2B at year-end 2023.

• Q3 2024 net loss was $96.7M ($1.17/share); nine-month net loss was $286.4M ($3.49/share).

• License and collaboration revenue was $14.3M for Q3 2024, down from $17.2M in Q3 2023.

• R&D expenses were $94.3M in Q3 2024, down from $100.1M in Q3 2023.

• Cash runway projected to fund operations into 2027.

Outlook and guidance

• Initial clinical data for BEAM-302 in AATD expected in 2025; BEAM-301 patient dosing to begin in early 2025.

• Additional BEAM-101 and ESCAPE data to be presented at ASH Annual Meeting in December 2024.

• Phase 1 enabling studies for ESCAPE technology to begin by year-end, followed by a healthy volunteer study.

• Operating expenses projected to increase with continued clinical development and manufacturing scale-up.

• Cash runway expected to fund operations for at least the next 12 months; additional capital may be needed for long-term growth.